Hormonal, metabolic and genetic predictors of metformin efficacy in patients with diabetes mellitus and cancer

Aims.

1. To compare hormonal and metabolic profile of type 2 diabetes mellitus patients (T2DM) with or without neoplastic processes with the data from screening for SNPs affecting sensitivity to metformin.
2. To compare the abovementioned parameters including relevant genotype frequency in patients with positive and negative response to metformin.

Materials and Methods.
A total of 167 patients, all female, aged 43 to 88 years in menopause no shorter than 1 year, with or without history of T2DM were enrolled in this study. 156 patients underwent genetic screening for SNPs that were previously suggested as relevant to metformin efficacy. 55 patients received metformin 1000-1700 g daily with hormonal and metabolic monitoring and assessment of surrogate antineoplastic markers (such as endometrial thickness and mammographic density of mammary glands).
Results.
There was no unifying hormonal or metabolic phenotype for patients with given metformin-associated SNPs. However, we observed a certain trend for alterations in HOMA-IR and plasma estradiol levels. Dyslipidemia and elevated estradiol levels were positively associated with both types of positive response to metformin ? ?metabolic? and ?antineoplastic? ? though the latter was observed less frequently. Our data suggests that among 8 studied SNPs, the OCT1_R61C genotype (organic cation transporter-1) carriers require more close attention.
Conclusion.
Larger studies are required for further elucidation of the genetic background for metformin action in patients with various forms of cancer.

metformin, efficacy, type 2 diabetes mellitus, cancer, insulin resistance, estradiol, single nucleotide polymorphisms

1. 1. The Use of Medicines in the United States: Review of 2012. IMS Institute for Healthcare Informatics. May 2013, 50 pp. http://www.imshealth.com

2. Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005 апр.;330(7503):1304-1305. Available from: http://europepmc.org/abstract/MED/15849206 PubMed PMID: 15849206. doi: 10.1136/bmj.38415.708634.F7.

3. Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, et al. Metformin: multi-faceted protection against cancer.. Oncotarget 2011 дек.;2(12):896-917. Available from: http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=387 PubMed PMID: 22203527.

4. Шестакова М. В., Зилов А. В. Выбор оптимальной сахароснижающей терапии у пациентов с сахарным диабетом в дебюте заболевания. Consilium medicum. 2010; 12(12): 5–10 [Shestakova M.V., Zilov A.V. Vybor sacharosnizhajuschej terapii u pazientov s saharnym diabetom v debjute zabolevanija].

5. Берштейн Л.М. Диабет, ожирение и онкологическая заболеваемость: риски и антириски. Diabetes mellitus. 2012;(4):81–88 [Lev M. Berstein Diabet, ozhirenie I onkologicheskaya zabolevaemostj: riski i antiriski].

6. Scheen AJ, Lefebvre PJ. Oral antidiabetic agents. A guide to selection. Drugs 1998;55(2):225-236. Available from: http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+1115-70-4 PubMed PMID: 9506242. doi: org/10.2165/00003495-199855020-00004.

7. Ong CR, Molyneaux LM, Constantino MI, Twigg SM, Yue DK. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care 2006;29(11):2361-2364. Available from: http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+1115-70-4 PubMed PMID: 17065668. doi: org/10.2337/dc06-0827.

8. Christensen MMH, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 2011;21(12):837-850. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=01213011-201112000-00008 PubMed PMID: 21989078. doi: 10.1097/FPC.0b013e32834c0010.

9. Berstein LM, Iyevleva AG, Vasilyev D, Poroshina TE, Imyanitov EN. Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer. Cell Cycle 2013 окт.;12(23):3681-3688. Available from: http://antibodies.cancer.gov/apps/site/detail/CPTC-OTUB1-1#CPTC-OTUB1-1 PubMed PMID: 24145224. doi: 10.4161/cc.26868.

10. Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 2012;30(21):2593-2600. Available from: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2011.39.3769 doi: 10.1200/JCO.2011.39.3769.

11. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab 2008;93(3):792-800. Available from: http://europepmc.org/abstract/MED/18000088 PubMed PMID: 18000088. doi: 10.1210/jc.2007-1736.

12. GoDARTS , Diabetes U. Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2, Zhou K, Bellenguez C,Spencer CC, et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011;2011(43):117-120. Available from: http://europepmc.org/abstract/MED/21186350 PubMed PMID: 21186350. doi: 10.1038/ng.735.

13. Thameem F, Puppala S, Lehman DM, Stern MP, Blangero J, Abboud HE, et al. The Ser(326)Cys Polymorphism of 8-Oxoguanine Glycosylase 1 (OGG1) Is Associated with Type 2 Diabetes in Mexican Americans. Hum Hered 2010;70(2):97-101. Available from: http://europepmc.org/abstract/MED/20606456 PubMed PMID: 20606456. doi: 10.1159/000291964.

14. YuM U, Imyanitov EN, Vasilyev DA, Berstein LM. Polymorphic Markers Associated with Genes Responsible for Lipid and Carbohydrate Metabolism Disorders and Insulin Resistance in Cancer Patients. Molecular Biology (Mosk 2008;42(6):843-851. Available from: http://link.springer.com/10.1134/S0026893308060034 doi: 10.1134/S0026893308060034.

15. Le TN, Nestler JE, Strauss 3rd JF, Wickham 3rd EP. Sex hormone-binding globulin and type 2 diabetes mellitus. Trends Endocrinol Metab 2012;23(1):32-40. Available from: http://europepmc.org/abstract/MED/22047952 PubMed PMID: 22047952. doi: 10.1016/j.tem.2011.09.005.

16. Avery CL, He Q, North KE, Ambite JL, Boerwinkle E, Fornage M, et al. A phenomics-based strategy identifies loci on APOC1, BRAP, and PLCG1 associated with metabolic syndrome phenotype domains. PLoS Genet 2011;7(10). Available from: http://dx.plos.org/10.1371/journal.pgen.1002322 PubMed PMID: 22022282. doi: 10.1371/journal.pgen.1002322..

17. Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res 2011;13(6):223-225. Available from: http://breast-cancer-research.com/content/13/6/223 PubMed PMID: 22114898. doi: 10.1186/bcr2942.

18. Берштейн ЛМ, Васильев ДА, Коваленко ИГ, Порошина ТЕ, Кисельников КС, Бояркина МП и соавт. Влияние метформина и N-ацетилцистеина на маммографическую плотность молочных желез у женщин постменопаузального возраста. Вопросы онколщгии. 2012; (58):45-49 [Bershteĭn LM, Vasil'ev DA, Kovalenko IG, Poroshina TE, Kisel'nikov KS, Boiarkina MP, et al. Vlijanie metformina i N-acetilcisteina na mammographicheskuju plotnostj molochnyh zhelez u zhenschin postmenopausaljnogo vozrasta. Questions of Oncology. 2012;(58):45-49]. PubMed PMID: 22629827.

19. Берштейн ЛМ, Максимов СЯ, Данилова МА, Гершфельд ЭД, Бояркина МП, Хаджимба АС и соавт. Сравнение эффектов ингибиторов ароматазы и метформина при их неоадъювантном применении у больных раком эндометрия. Вопросы онкологии. 2011; (57):737-741. [Bershteyn LM, Maksimova SYa , Danilova MA, Gershfel'd ED, Boyarkina MP, Khadzhimba AS. Sravnenie effektov ingibitorov aromatazi i metformina pri ih neoadjuvantnom primenenii u boljnyh rakom endometrija. Questions of Oncology 2011;(57):737-741]. PubMed PMID: 22416390.

20. Cazzaniga M, DeCensi A, Pruneri G, Puntoni M, Bottiglieri L, Varricchio C. et al. The effect of metformin on apoptosis in a breast cancer presurgical trial. Br. J. Cancer 2013;109(11):2792-2797. Available from: http://www.nature.com/doifinder/10.1038/bjc.2013.657 doi: 10.1038/bjc.2013.657.

21. Wahdan-Alaswad R, Fan Z, Edgerton SM, Liu B, Deng XS, Arnadottir SS. et al. Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle 2013;12(24):3759-3769. Available from: http://www.landesbioscience.com/journals/cc/abstract.php?id=26641 PubMed PMID: 24107633. doi: 10.4161/cc.26641.